Targeting the PI3K pathway in cancer: are we making headway?

Targeting the PI3K pathway in cancer: are we making headway?Targeting the PI3K pathway in cancer: are we making headway?, Published online: 06 March 2018; doi:10.1038/nrclinonc.2018.28The PI3K–AKT–mTOR pathway has key roles in tumorigenesis and is dysregulated in most cancers. Consequently, numerous drugs that target key nodes of this pathway have been developed, although few of these agents have been approved for the treatment of cancer. Herein, the authors review the current experience with anticancer therapies that target the PI3K–AKT–mTOR pathway, discuss the challenges that have limited the clinical translation of these agents, and provide perspectives for the future development of these drugs.
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: Source Type: research